Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them are FDA-approved.

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents ...

An active acupressure intervention offers clinical benefits for patients with rosacea when combined with pharmacotherapy.

Quadrivalent HPV vaccination before pregnancy is associated with a lower risk for adverse pregnancy outcomes, including preterm birth.

Undeclared pharmacologically active ingredients are detected in one-third of over-the-counter skin products marketed online.

Tralokinumab for AD was associated with sustained improvements in disease severity and no new safety signals at 12 months in a real-life study.

Congenital TORCH infections appear to be associated with an increased risk for intellectual disability and autism.

The lifetime risk for heart failure is increasing, and prevalence is projected to continue accelerating, according to a recent report.

While TB and meningitis are rare among patients receiving systemic psoriasis therapies, IL-17 inhibitors increase the risk for candidiasis.

The use of vibration anesthesia in patients undergoing cryotherapy was associated with pain reductions when compared with cryotherapy alone.

The FDA has expanded the approval of Rhapsido (remibrutinib) to include symptomatic dermographism in adults inadequately controlled by H1 antihistamines, backed by phase 3 RemIND trial data.